转移性三阴性乳腺癌的靶向治疗:系统性综述

IF 1.9 4区 医学 Q3 OBSTETRICS & GYNECOLOGY Breast Journal Pub Date : 2024-07-11 DOI:10.1155/2024/9083055
Anna Martha Hammershøi Madsen, Rikke Helene Løvendahl Eefsen, Dorte Nielsen, Iben Kümler
{"title":"转移性三阴性乳腺癌的靶向治疗:系统性综述","authors":"Anna Martha Hammershøi Madsen,&nbsp;Rikke Helene Løvendahl Eefsen,&nbsp;Dorte Nielsen,&nbsp;Iben Kümler","doi":"10.1155/2024/9083055","DOIUrl":null,"url":null,"abstract":"<div>\n <p><i>Introduction</i>. Triple-negative breast cancer (TNBC) is a subgroup of breast cancer characterized by the absence of estrogen and the human epidermal 2 receptor and also a lack of targeted therapy options. Chemotherapy has so far been the only approved treatment option, and patients with metastatic cancer have a dismal prognosis with a median overall survival (OS) of approximately 14 months. Identification of druggable targets for metastatic TNBC is therefore of special interest. <i>Methods</i>. A systematic search was performed, to review the existing evidence on targeted therapies in metastatic TNBC. <i>Results</i>. A total of 37 phase 2/3 studies were identified, evaluating 29 different targeted agents. In this review, results on progression free survival (PFS) and OS are presented. <i>Conclusion</i>. In most of the studies included, no improvement was observed for neither PFS nor OS; however, a few studies did show improvement with targeted agents and have led to new treatment options in subgroups of patients. The antibody drug conjugate, sacituzumab govitecan, demonstrated superior PFS and OS in comparison to chemotherapy. Immunotherapy with checkpoint inhibitors such as atezolizumab and pembrolizumab is now recommended as a first-line treatment option for patients with expression a PD-L1 positive tumor. Finally, the poly adenosine diphosphate-ribose polymerase (PARP) inhibitors talazoparib and olaparib are recommended, as first-line treatment options in patients with metastatic breast cancer and a germline BRCA mutation, but an immune checkpoint inhibitor should be considered for the subset of these patients who are PD-L1 positive.</p>\n </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/9083055","citationCount":"0","resultStr":"{\"title\":\"Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review\",\"authors\":\"Anna Martha Hammershøi Madsen,&nbsp;Rikke Helene Løvendahl Eefsen,&nbsp;Dorte Nielsen,&nbsp;Iben Kümler\",\"doi\":\"10.1155/2024/9083055\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><i>Introduction</i>. Triple-negative breast cancer (TNBC) is a subgroup of breast cancer characterized by the absence of estrogen and the human epidermal 2 receptor and also a lack of targeted therapy options. Chemotherapy has so far been the only approved treatment option, and patients with metastatic cancer have a dismal prognosis with a median overall survival (OS) of approximately 14 months. Identification of druggable targets for metastatic TNBC is therefore of special interest. <i>Methods</i>. A systematic search was performed, to review the existing evidence on targeted therapies in metastatic TNBC. <i>Results</i>. A total of 37 phase 2/3 studies were identified, evaluating 29 different targeted agents. In this review, results on progression free survival (PFS) and OS are presented. <i>Conclusion</i>. In most of the studies included, no improvement was observed for neither PFS nor OS; however, a few studies did show improvement with targeted agents and have led to new treatment options in subgroups of patients. The antibody drug conjugate, sacituzumab govitecan, demonstrated superior PFS and OS in comparison to chemotherapy. Immunotherapy with checkpoint inhibitors such as atezolizumab and pembrolizumab is now recommended as a first-line treatment option for patients with expression a PD-L1 positive tumor. Finally, the poly adenosine diphosphate-ribose polymerase (PARP) inhibitors talazoparib and olaparib are recommended, as first-line treatment options in patients with metastatic breast cancer and a germline BRCA mutation, but an immune checkpoint inhibitor should be considered for the subset of these patients who are PD-L1 positive.</p>\\n </div>\",\"PeriodicalId\":56326,\"journal\":{\"name\":\"Breast Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-07-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/9083055\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/2024/9083055\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/9083055","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介三阴性乳腺癌(TNBC)是乳腺癌的一个亚组,其特点是缺乏雌激素和人类表皮2受体,也缺乏靶向治疗选择。迄今为止,化疗是唯一获得批准的治疗方案,而转移性癌症患者的预后很差,中位总生存期(OS)约为 14 个月。因此,确定转移性 TNBC 的可治疗靶点特别重要。研究方法对转移性 TNBC 靶向疗法的现有证据进行系统检索。结果。共确定了 37 项 2/3 期研究,评估了 29 种不同的靶向药物。本综述介绍了无进展生存期(PFS)和OS的结果。结论在纳入的大多数研究中,PFS 和 OS 均未见改善;但也有少数研究显示靶向药物的治疗效果有所改善,并为亚组患者带来了新的治疗选择。与化疗相比,抗体药物共轭物sacituzumab govitecan的PFS和OS均有改善。阿特珠单抗(atezolizumab)和彭博单抗(pembrolizumab)等检查点抑制剂的免疫疗法现已被推荐为表达 PD-L1 阳性肿瘤患者的一线治疗方案。最后,建议将聚腺苷二磷酸核糖聚合酶(PARP)抑制剂talazoparib和olaparib作为转移性乳腺癌和种系BRCA突变患者的一线治疗方案,但对于PD-L1阳性的这些患者中的一部分,应考虑使用免疫检查点抑制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review

Introduction. Triple-negative breast cancer (TNBC) is a subgroup of breast cancer characterized by the absence of estrogen and the human epidermal 2 receptor and also a lack of targeted therapy options. Chemotherapy has so far been the only approved treatment option, and patients with metastatic cancer have a dismal prognosis with a median overall survival (OS) of approximately 14 months. Identification of druggable targets for metastatic TNBC is therefore of special interest. Methods. A systematic search was performed, to review the existing evidence on targeted therapies in metastatic TNBC. Results. A total of 37 phase 2/3 studies were identified, evaluating 29 different targeted agents. In this review, results on progression free survival (PFS) and OS are presented. Conclusion. In most of the studies included, no improvement was observed for neither PFS nor OS; however, a few studies did show improvement with targeted agents and have led to new treatment options in subgroups of patients. The antibody drug conjugate, sacituzumab govitecan, demonstrated superior PFS and OS in comparison to chemotherapy. Immunotherapy with checkpoint inhibitors such as atezolizumab and pembrolizumab is now recommended as a first-line treatment option for patients with expression a PD-L1 positive tumor. Finally, the poly adenosine diphosphate-ribose polymerase (PARP) inhibitors talazoparib and olaparib are recommended, as first-line treatment options in patients with metastatic breast cancer and a germline BRCA mutation, but an immune checkpoint inhibitor should be considered for the subset of these patients who are PD-L1 positive.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Breast Journal
Breast Journal 医学-妇产科学
CiteScore
4.00
自引率
0.00%
发文量
47
审稿时长
4-8 weeks
期刊介绍: The Breast Journal is the first comprehensive, multidisciplinary source devoted exclusively to all facets of research, diagnosis, and treatment of breast disease. The Breast Journal encompasses the latest news and technologies from the many medical specialties concerned with breast disease care in order to address the disease within the context of an integrated breast health care. This editorial philosophy recognizes the special social, sexual, and psychological considerations that distinguish cancer, and breast cancer in particular, from other serious diseases. Topics specifically within the scope of The Breast Journal include: Risk Factors Prevention Early Detection Diagnosis and Therapy Psychological Issues Quality of Life Biology of Breast Cancer.
期刊最新文献
Relationship Between Mitochondrial Biological Function and Breast Cancer Unveiling miRNA30b’s Role in Suppressing ADAM12 to Combat Triple-Negative Breast Cancer Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer Brain Metastasis in Triple-Negative Breast Cancer Duration of Breastfeeding and Risk Reduction of Breast Cancer among Mothers Who Have Ever Breastfed: A Case-Control Study Conducted in Bahir Dar, Ethiopia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1